Search Within

Weinberg Fellows

  1. "Jae Park"
Formats
  1. Meeting Abstract (32)
  2. Journal Article (26)
  3. Book Section (2)
  4. Correspondence (1)
  5. Research Letter (1)
Groups
  1. Adult Leukemia (62)
  2. Center for Hematologic Malignancies (62)
  3. Department of Medicine (62)
  4. Hematologic Malignancies, Division of (62)
  5. Hematology-Oncology Fellows (62)
  6. GSK Faculty (26)

More Groups

People
  1. Jae Park (62)
  2. Mark Geyer (48)
  3. Martin Tallman (17)
  4. Renier Brentjens (16)
  5. Maria Palomba (15)
  6. Sergio Giralt (14)

More People

Years
  1. 2025 (6)
  2. 2024 (7)
  3. 2023 (9)
  4. 2022 (4)
  5. 2021 (5)
  6. 2020 (6)

More Years

Publications
  1. Blood (28)
  2. Leukemia and Lymphoma (5)
  3. Blood Advances (4)
  4. Journal of Clinical Oncology (3)
  5. Abeloff’s Clinical Oncology. 6th ed (1)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. Elsevier Inc. (5)
  3. Taylor & Francis Group (5)
  4. American Society of Clinical Oncology (3)
  5. Nature Publishing Group (3)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (62)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
    Journal Article

    Yi, F.; Cohen, T.; Zimmerman, N.; Dündar, F.; Zumbo, P.; Eltilib, R.; Brophy, E. J.; Arkin, H.; Feucht, J.; Gormally, M. V.; more...
    Nature Cancer (2025)

    Fulltext@MSK | Save
  • Barriers to chimeric antigen receptor T-cell therapy
    Research Letter

    Valtis, Y. K.; Chin, K. K.; Nemirovsky, D.; Devlin, S. M.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
    Journal Article

    Raj, S. S.; Fei, T.; Fried, S.; Ip, A.; Fein, J. A.; Leslie, L. A.; Alarcon Tomas, A.; Leithner, D.; Peled, J. U.; Corona, M.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Enhancing the persistence and anti-tumor efficacy of CAR-T and CAR-NK cells through genetic disruption of death receptors
    Meeting Abstract

    Cohen, T. D.; Yi, F.; Zumbo, P.; Etilib, R.; Arkin, H.; Gormally, M.; Hackett, C. S.; Kropp, K.; Etxeberria, I.; Chandran, S. S.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Journal Article

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G. K.; Borge, P. D.; Geyer, M.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia
    Journal Article

    Chin, K. K.; Valtis, Y.; Derkach, A.; Yisraeli Salman, M.; Boussi, L.; Ciervo, J.; Geyer, M. B.; Park, J. H.; Tallman, M. S.; Glass, J. L.; more...
    Blood Neoplasia (2024)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CD371-targeted CAR T-cells secreting interleukin-18 exhibit robust expansion and disease clearance in patients with refractory acute myeloid leukemia
    Meeting Abstract

    Geyer, M. B.; Dewolf, S.; Mi, X.; Shaffer, B. C.; Cadzin, B.; McAvoy, D.; Hosszu, K. K.; Weis, K.; Lorenc, R.; Lewis, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save